Tirzepatide vs Mazdutide

Tirzepatide vs Mazdutide: Overview

Tirzepatide and mazdutide are both dual-receptor agonists that target incretin pathways, representing the next generation of multi-agonist peptide therapies for metabolic disease. Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Mazdutide (also known as IBI362 or LY3305677), developed by Innovent Biologics in collaboration with Eli Lilly, is a dual GLP-1/glucagon receptor agonist. The comparison of mazdutide vs tirzepatide is of particular interest because these agents employ different dual-receptor strategies to achieve metabolic benefits — one targeting GIP alongside GLP-1, the other targeting glucagon alongside GLP-1.

The rationale for comparing tirzepatide vs mazdutide lies in the fundamental question of which co-receptor system — GIP or glucagon — produces optimal metabolic outcomes when combined with GLP-1 receptor agonism. Research suggests that GIP receptor activation and glucagon receptor activation engage distinct but complementary metabolic pathways, with differing effects on energy expenditure, hepatic metabolism, and adipose tissue biology. As both compounds have generated substantial clinical data, a comparative analysis provides insights into how different multi-agonist strategies translate into clinical outcomes.

Both agents are positioned at the forefront of multi-receptor agonist pharmacotherapy, and their respective clinical programmes have produced compelling efficacy and safety data. The growing evidence base enables a detailed comparison of these two approaches, particularly as mazdutide advances through its global clinical development programme.

Mechanism of Action

Tirzepatide is a 39-amino acid synthetic peptide based on the native GIP sequence, engineered with modifications that confer cross-reactivity at the GLP-1 receptor. It activates the GIP receptor at full potency and the GLP-1 receptor as a biased agonist with approximately five-fold reduced potency relative to native GLP-1. The dual GIP/GLP-1 receptor engagement stimulates glucose-dependent insulin secretion from pancreatic beta cells through both incretin pathways, while GLP-1 receptor activation additionally suppresses glucagon release, slows gastric emptying, and promotes central satiety. GIP receptor activation is thought to influence adipose tissue metabolism and may contribute to enhanced insulin sensitivity through mechanisms distinct from GLP-1 signalling.

Mazdutide takes a fundamentally different dual-agonist approach by combining GLP-1 receptor agonism with glucagon receptor agonism. The glucagon receptor component introduces metabolic effects that are mechanistically distinct from GIP receptor activation. Glucagon receptor agonism promotes hepatic glycogenolysis and gluconeogenesis acutely, but in the context of concurrent GLP-1 receptor activation, the net metabolic effect is characterised by increased energy expenditure, enhanced hepatic lipid oxidation, and reduced hepatic steatosis — effects that may be particularly beneficial for metabolic-associated steatotic liver disease. The GLP-1 receptor component counterbalances glucagon’s hyperglycaemic potential while providing the appetite-suppressive and insulin-secretory effects characteristic of GLP-1 agonism.

The key mechanistic distinction between tirzepatide and mazdutide thus centres on whether GIP or glucagon co-agonism provides greater metabolic benefit when combined with GLP-1 receptor activation. Preclinical data indicates that glucagon receptor engagement may confer advantages in hepatic fat reduction and energy expenditure, while GIP receptor engagement may enhance insulin sensitivity and adipose tissue function.

Clinical Evidence

Tirzepatide’s clinical evidence is extensive, supported by the SURPASS programme (type 2 diabetes) and the SURMOUNT programme (obesity). The SURPASS-2 trial demonstrated tirzepatide’s superiority over semaglutide 1.0 mg in HbA1c reduction and body weight loss, establishing tirzepatide as one of the most potent glucose-lowering agents available. The SURMOUNT-1 trial demonstrated mean body weight reductions of 15.0%, 19.5%, and 20.9% with tirzepatide 5, 10, and 15 mg respectively over 72 weeks in participants with obesity but without diabetes.

Mazdutide’s clinical programme has advanced rapidly, particularly in China, where the compound has been developed through multiple phase 2 and phase 3 trials. A phase 2 randomised controlled trial by Ji et al. evaluated mazdutide 9 mg in Chinese adults with a BMI ≥30 kg/m² without diabetes, demonstrating significant body weight reductions. Two pivotal phase 3 trials published in Nature in 2026 have substantially expanded the evidence base: Zhu et al. reported results of mazdutide versus placebo in Chinese adults with type 2 diabetes, and Guo et al. compared mazdutide directly against dulaglutide in the same population, demonstrating superiority of mazdutide in both glycaemic control and weight reduction.

The DREAMS-3 trial represents a particularly significant development, directly comparing mazdutide against semaglutide for the treatment of type 2 diabetes and obesity. While full results are pending, the trial design and baseline data have been published, indicating a well-powered comparison that will provide critical head-to-head evidence. No direct clinical comparison of mazdutide vs tirzepatide has been conducted, though network meta-analyses incorporating both agents are beginning to emerge.

Efficacy Comparison

Comparing the weight loss efficacy of mazdutide vs tirzepatide requires careful cross-trial interpretation, as these agents have been studied in different populations and trial designs. Tirzepatide has demonstrated body weight reductions of approximately 20–22% at its highest dose (15 mg) in global obesity trials, with the SURMOUNT-1 trial establishing a new benchmark for pharmacological weight loss. In the SURMOUNT-2 trial involving participants with type 2 diabetes and obesity, tirzepatide 15 mg achieved approximately 14.7% body weight reduction.

Mazdutide’s weight loss data, primarily from Chinese clinical populations, has demonstrated body weight reductions in the range of 8–15% depending on the dose and study population. The phase 2 data with mazdutide 9 mg showed clinically meaningful weight reductions, and the phase 3 trials have confirmed dose-dependent weight loss. A network meta-analysis by Abulehia et al. comparing incretin-based dual and triple agonists in overweight or obese individuals has provided indirect comparative data, though the differing ethnic compositions of the study populations complicate direct comparisons.

Regarding glycaemic control, both agents have demonstrated robust HbA1c reductions. Tirzepatide achieves HbA1c reductions of up to 2.4 percentage points, while mazdutide’s phase 3 data has shown comparable glycaemic improvements in Chinese populations with type 2 diabetes. A comparative efficacy analysis by Liu et al. examining incretin drugs on glycaemic control, body weight, and blood pressure provided a network meta-analytic framework for contextualising these results across agents and populations.

Safety and Tolerability

Both tirzepatide and mazdutide share the gastrointestinal adverse event profile common to GLP-1 receptor-active therapies. Nausea, vomiting, diarrhoea, and decreased appetite are the most frequently reported adverse events with both compounds, with symptoms typically most pronounced during dose escalation phases.

Tirzepatide’s safety profile has been characterised across the large SURPASS and SURMOUNT programmes, with gastrointestinal events leading to discontinuation in approximately 4–7% of participants. The dual GIP/GLP-1 mechanism has not introduced unique safety signals beyond those expected with GLP-1 receptor agonism, though the cardiovascular outcome trial (SURPASS-CVOT) continues to generate long-term safety data.

Mazdutide’s glucagon receptor agonist component introduces theoretical considerations regarding hepatic glucose output and potential hyperglycaemic effects. However, clinical data indicates that the GLP-1 receptor component effectively counterbalances glucagon-mediated hyperglycaemia, with net glucose-lowering effects observed across clinical trials. The phase 3 data have reported a tolerability profile broadly consistent with other incretin-based therapies, with gastrointestinal events as the predominant adverse effects. The impact of glucagon receptor agonism on hepatic lipid metabolism represents a potential safety advantage, as reduced hepatic steatosis could translate into improved liver-related outcomes.

Pharmacokinetics

Tirzepatide is administered via once-weekly subcutaneous injection, with a half-life of approximately 5 days (120 hours) achieved through albumin binding via its C-20 fatty diacid moiety. The molecule has a molecular weight of approximately 4.8 kDa, and steady-state plasma concentrations are reached after approximately four weeks of weekly dosing. Tirzepatide exhibits dose-proportional pharmacokinetics across its approved dose range of 5–15 mg.

Mazdutide is also administered via subcutaneous injection, with a half-life that supports once-weekly dosing. The compound incorporates structural modifications to both its GLP-1 and glucagon agonist components to achieve extended duration of action. The pharmacokinetic profile has been characterised in phase 1 studies, including a high-dose phase 1 trial by Bhattachar et al. that evaluated the pharmacokinetics and pharmacodynamics of mazdutide at doses designed to maximise weight loss efficacy while maintaining tolerability.

Both agents share the subcutaneous route of administration and once-weekly dosing frequency, making their pharmacokinetic profiles comparable from a practical dosing perspective. The key pharmacokinetic difference lies in their molecular design strategies and the distinct tissue distribution patterns that may arise from their different receptor-binding profiles and molecular architectures.

Current Research Status

Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023), with an extensive pipeline of ongoing trials investigating expanded indications including metabolic-associated steatotic liver disease, heart failure with preserved ejection fraction, and obstructive sleep apnoea. The SURPASS-CVOT cardiovascular outcome trial represents a major ongoing investigation that will provide definitive cardiovascular safety and efficacy data.

Mazdutide has received regulatory approval in China for type 2 diabetes and is undergoing continued clinical development through global phase 3 trials. The DREAMS programme represents the primary registrational pathway, with the DREAMS-3 trial directly comparing mazdutide against semaglutide providing particularly important data. Global regulatory submissions outside China are anticipated as the clinical programme matures. Mazdutide’s dual GLP-1/glucagon mechanism positions it uniquely among multi-agonist therapies, with potential advantages in hepatic metabolic outcomes that could differentiate it from GIP/GLP-1 dual agonists.

Summary

The comparison of tirzepatide and mazdutide illustrates how different dual-receptor agonist strategies produce distinct metabolic profiles. Tirzepatide’s GIP/GLP-1 dual agonism has produced among the most impressive weight loss and glycaemic outcomes in clinical development, with approximately 20% body weight reduction in obesity trials and robust HbA1c reductions. Mazdutide’s GLP-1/glucagon dual agonism engages energy expenditure and hepatic metabolism pathways through glucagon receptor activation, with clinically meaningful weight loss and glycaemic improvements demonstrated in phase 2 and phase 3 trials. Both agents share the class-typical gastrointestinal tolerability profile. Direct head-to-head comparison data are not yet available, and cross-trial comparisons are limited by differing study populations. The ongoing maturation of mazdutide’s clinical programme will provide increasingly definitive data to characterise this comparison.

References

• Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. PMID: 35658024
• Frías JP et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. PMID: 34170647
• Ji L et al. (2026). Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m² but without diabetes: A phase 2 randomized controlled trial. Med. PMID: 41875890
• Zhu D et al. (2026). Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. PMID: 41407859
• Guo L et al. (2026). Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. PMID: 41407860
• Luo Y et al. (2026). Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial. Contemporary Clinical Trials. PMID: 41260459
• Bhattachar SN et al. (2025). Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial. Diabetes, Obesity and Metabolism. PMID: 40832785
• Liu S et al. (2025). Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity. Frontiers in Endocrinology. PMID: 39968298